GU Cancers Symposium

Based on findings from the phase 3 CheckMate 9ER trial, the FDA approved nivolumab/cabozantinib for use in the first-line setting for patients with advanced RCC.

The FDA is scheduled to make a decision on a new drug application for 18F-DCFPyL on or before May 28, 2021.

The FDA recently approved a less-frequent, fixed dose of durvalumab at 1500 mg every 4 weeks for use in patients with metastatic urothelial carcinoma.

After adjusting for crossover using a preplanned sensitivity analysis, investigators for the pivotal phase 3 TITAN trial found a 48% reduction in the risk of death in patients treated with apalutamide plus ADT versus ADT alone.

The antibody-drug conjugate was previously granted an accelerated approval by the FDA in this setting based on results from the phase 2 EV-201 trial.

“These findings indicate that darolutamide is an effective and well-tolerated androgen receptor inhibitor as an early treatment option for patients with [nmCRPC],” reported Neal D. Shore, MD.

The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.

The investigational tubulin inhibitor was also safe and well tolerated at continuous daily dosing.

The higher starting dose of lenvatinib was also associated with a prolonged time to deterioration.

The FDA approved darolutamide in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

The novel agent eganelisib led to higher response rates with nivolumab in PD-L1–low patients with metastatic urothelial carcinoma.

Determining the optimal treatment approach for patients with non–clear cell renal cell carcinoma has long been an unmet medical need in the field.

With several immunotherapy-based combinations now available in frontline RCC, new options are needed for patients who progress.

There was a trend toward better overall survival outcomes with the apalutamide/abiraterone combination in certain prespecified biomarker subgroups.

Genomics may ultimately play an important role in determining recurrence risk in patients who undergo surgery for localized kidney cancer, according to Brian Rini, MD, of Cleveland Clinic.

Stereotactic body radiotherapy shows rates of acute toxicity that are similar to those of conventionally fractionated radiotherapy in men with low- or intermediate-risk localized prostate cancer, according to early findings from an international randomized study.

While neoadjuvant chemotherapy has been associated with a survival benefit in patients with muscle-invasive bladder cancer, patient selection needs to improve to optimize clinical outcomes and minimize costs, according to Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas.

Analysis of a large, real-world patient database reveals interesting findings about the current management of metastatic castration-resistant prostate cancer, including a few surprises. Celestia Higano, MD, said 77% of patients received first-line therapy.

“HPV6 positive serology was associated with an increased odds of bladder cancer, and I saw a trend in that it was younger patients with bladder cancer who had the HPV6 positivity,” says Lael S. Reinstatler, MD, MPH, in this video interview.

The Decipher genomic classifier is as effective in predicting prostate cancer metastasis and mortality in African-American men as it is in Caucasian men, according to new study findings reported by Stephen Freedland, MD, of Cedars-Sinai Medical Center, Los Angeles.

Urology Times video interviews will feature expert discussion on prostate, kidney, and bladder cancer research from the Genitourinary Cancers Symposium in San Francisco.